The deal range was $3.35-$3.70. Morgan Stanley, Goldman Sachs, BofA and TD Cowen acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Reports Non-Cash Impairment Losses
- Sana Biotechnology announces $75M common stock offering
- Promising Developments and FDA Engagement Bolster Buy Rating for Sana Biotechnology
- Sana Biotechnology announces publication on clinical data from transplantation
- Positive Outlook on Sana Biotechnology Driven by Promising T1D Program and Allogeneic CAR-T Advancements